664 692
[37]
Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med 2016;5:182–91.
[38]
Mukherji D, Pezaro CJ, Shamseddine A, de Bono JS. New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat Rev 2013;39:578–83.
[39]
Fung C, Dale W, Mohile SG. Prostate cancer in the elderly patient. J Clin Oncol 2014;32:2523–30.[40]
Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014;25: 429–34.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 5 6 – 6 6 4
664